Most Read Articles
4 days ago
The use of capsule endoscopy (CE) appears to be effective in the diagnosis of iron deficiency anaemia (IDA), yielding a 33.9-percent yield in this study, with 65.8 percent of patients undergoing further workup and 12.7 percent requiring therapeutic intervention.
Tristan Manalac, 3 days ago
Minimally invasive pancreatectomy (MIP) offers a feasible alternative to open pancreatectomy (OP) for the treatment of pancreatic neuroendocrine neoplasms (PNEN), according to a recent Singapore study has found.
Yesterday
The perception that proton pump inhibitors (PPIs) cause multiple serious adverse effects (AEs) is supported by many internists, who then recommend treatment cessation even in patients at high risk for upper gastrointestinal bleeding (UGIB), reveals a study.
21 May 2020
At the 13th Annual Scientific Meeting of the Malaysian Osteoporosis Society (MOS), Dr Chan Siew Pheng discussed the role of alfacalcidol (One-Alpha®) in the treatment of osteoporosis (OP) and presented several patient profiles where alfacalcidol exhibited efficacy in increasing bone mineral density (BMD).

Pharmacist presence in clinic reduces polypharmacy in multiple myeloma patients

05 May 2020
When is enough really enough for patients in light of the growing shift towards polypharmacy?

The rate of polypharmacy is high among patients with multiple myeloma, according to a study. However, comanagement with a pharmacist reduces the number of all medications, particularly those that are not related to myeloma.

A retrospective chart review was performed in an urban academic cancer centre using electronic records of 44 patients in the traditional physician-managed clinic and 57 patients in the collaborative physician-pharmacist clinic.

On average, patients in the collaborative clinic used fewer medications (9 vs 7; p=0.045). The median number of medications for the treatment of myeloma was higher (2 vs 4; p<0.001), but the number of nonmyeloma-related medications was lower (7 vs 3; p<0.0001) in the collaborative clinic.

Although both clinics demonstrated high rates of polypharmacy (93 percent vs 84 percent; p=0.22), the collaborative clinic had a substantially lower rate of polypharmacy of nonmyeloma medications (71 percent vs 33 percent; p=0.0003), including both minor (five to nine medications: 48 percent vs 28 percent; p=0.06) and major (≥10 medications: 23 percent vs 5 percent; p=0.02) polypharmacy.

On the other hand, patients in the collaborative clinic had significantly higher minor polypharmacy of myeloma-related medications (32 percent vs 2 percent; p=0.0002).

In multivariate analysis, patients in the collaborative clinic had a reduced risk of having a higher number of medications (relative risk [RR], 0.79, 95 percent confidence interval [CI], 0.67–0.93; p=0.004), a lower risk of having any polypharmacy of nonmyeloma-related medications (RR, 0.41, 95 percent CI, 0.25–0.67; p<0.001) and a lower risk of receiving potentially inappropriate medication (RR, 0.62, 95 percent CI, 0.41–0.95; p=0.029).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
4 days ago
The use of capsule endoscopy (CE) appears to be effective in the diagnosis of iron deficiency anaemia (IDA), yielding a 33.9-percent yield in this study, with 65.8 percent of patients undergoing further workup and 12.7 percent requiring therapeutic intervention.
Tristan Manalac, 3 days ago
Minimally invasive pancreatectomy (MIP) offers a feasible alternative to open pancreatectomy (OP) for the treatment of pancreatic neuroendocrine neoplasms (PNEN), according to a recent Singapore study has found.
Yesterday
The perception that proton pump inhibitors (PPIs) cause multiple serious adverse effects (AEs) is supported by many internists, who then recommend treatment cessation even in patients at high risk for upper gastrointestinal bleeding (UGIB), reveals a study.
21 May 2020
At the 13th Annual Scientific Meeting of the Malaysian Osteoporosis Society (MOS), Dr Chan Siew Pheng discussed the role of alfacalcidol (One-Alpha®) in the treatment of osteoporosis (OP) and presented several patient profiles where alfacalcidol exhibited efficacy in increasing bone mineral density (BMD).